UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 6-K
________________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2021
Commission File Number: 001-38281
ERYTECH Pharma S.A.
(Translation of registrant’s name into English)
________________________
60 Avenue Rockefeller
69008 Lyon France
(Address of principal executive office)
________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
S Form 20-F £ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): £
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): £
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
Press Release
On May 25, 2021, ERYTECH Pharma S.A. issued a press release announcing the date of its combined shareholders’ meeting, the availability of preparatory documents for the meeting and certain other related details. A copy of this press release is attached to this Form 6-K as Exhibit 99.1.
EXHIBITS
| Exhibit | Description | |||||||
99.1 | Press Release dated May 25, 2021. | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ERYTECH Pharma S.A. | ||||||||||||||||||||
Date: | May 26, 2021 | By: | /s/ Eric Soyer | |||||||||||||||||
Name Eric Soyer | ||||||||||||||||||||
Title: Chief Financial Officer and Chief Operating Officer | ||||||||||||||||||||
Exhibit 99.1
 | PRESS RELEASE | ||||
ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 25, 2021
Live webcast of the Shareholders’ Meeting
Availability of the preparatory documents for the Shareholders’ Meeting
Lyon (France), May 25, 2020 – Erytech Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, is announcing that its Combined Shareholders’ Meeting will be held in French in closed session at 2pm CEST on Friday, June 25, 2021, and also the associated details.
In compliance with recent French legislation1 and per the recommendations of the French financial markets authority (Autorité des Marchés Financiers or AMF), Erytech confirms that its Annual Ordinary and Extraordinary Shareholders Meeting will take place at 2pm (Paris time) on June 25, 2021 in a closed session, without any shareholders being present in person. Please note that the AMF strongly encourages shareholders to vote, as such right is a fundamental prerogative of each shareholder, by means of distance voting, with all votes to be cast ahead of the Shareholders’ Meeting.
Voting procedures
For your vote to count:
I.Voting or giving proxy by mail with the paper form
–For holders of registered shares: registered shareholders must return their completed and signed postal voting form or proxy form, using the T envelope provided with the notice of meeting, to Société Générale Securities Services, Service des Assemblées, CS 30812, 44308 Nantes Cedex 03, FRANCE.
–For holders of bearer shares: holders of bearer shares must return their single postal voting form or proxy form, completed and signed, to the authorized financial intermediary who manages their securities account. The financial intermediary will prove that they are shareholders and will return the form to Société Générale Securities Services.
These documents must reach us by June 22, 2021.
In the event that a proxy is given to a natural or legal person, the proxy holder shall send its voting instruction to Société Générale, by e-mail to the following address: assemblees.generales@sgss.socgen.com. The deadline for receipt is June 21, 2021.
II. Voting or giving proxy by internet
The VOTACCESS secure platform will be open from 9:00 a.m. on June 7, 2021 until 3:00 p.m., Paris time, on June 24, 2021.
However, in order to avoid any possible saturation of the VOTACCESS site, shareholders are advised not to wait until the day before the meeting to vote.
1 Law of 23 March 2020 to respond to COVID-19 and decree No. 2020-321 dated 25 March 2020 as amended and extended by decree No. 2020-1497 dated December 2, 2020 and by decree No. 2021-255 dated March 9, 2021
Shareholders’ Meeting to be held in closed session without any shareholders being present in person
All the requisite arrangements for the Shareholders’ Meeting to proceed smoothly amid the current health situation have been made:
–shareholders will be able to follow events at the Shareholders’ Meeting live in a webconference. The registration link for this event will be available on the company's website soon.
–for written questions, because it will not be possible for shareholders to ask questions during the Shareholders’ Meeting, Erytech recommends that they should send in written questions to the registered office by registered letter with return receipt requested to the Chairman of the Board of Directors or by email to legal@erytech.com no later than two business days prior to the Shareholders’ Meeting (i.e., by June 23, 2021). Given the exceptional circumstances, the Company is asking shareholders to email in their questions, wherever possible, attaching a certificate proving that they own shares in Erytech.
Availability of the documents for the Shareholders’ Meeting
The notice of meeting including the agenda and the draft resolutions, together with the principal details for attending and voting at the Combined Shareholders’ Meeting was published in the French Bulletin of Legal Announcements no. 60 on May 19, 2021.
Shareholders have access to the preparatory and information documents for the Shareholders’ Meeting as provided for by law and the regulations. They may also be viewed on the Company website at: https://investors.erytech.com/general-meeting
About ERYTECH and eryaspase
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.
The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing.
Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer. The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL.
ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
For more information, please visit www.erytech.com
CONTACTS
ERYTECH Eric Soyer CFO & COO | LifeSci Advisors, LLC Investor Relations Corey Davis, Ph.D. | NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor relations Nicolas Merigeau Media relations | ||||||
+33 4 78 74 44 38 investors@ERYTECH.com | +1 (212) 915 - 2577 cdavis@lifesciadvisors.com | +33 1 44 71 94 94 ERYTECH@newcap.eu | ||||||
